Holen Sie sich die Stockscreener-App
1.91
8.52%
0.15
Handel nachbörslich:
2.00
0.09
+4.71%
Schlusskurs vom Vortag:
$1.76
Offen:
$1.78
24-Stunden-Volumen:
9.88M
Relative Volume:
2.96
Marktkapitalisierung:
$314.98M
Einnahmen:
$101.21M
Nettoeinkommen (Verlust:
$-569.00K
KGV:
-95.50
EPS:
-0.02
Netto-Cashflow:
$-56.88M
1W Leistung:
-18.72%
1M Leistung:
-20.42%
6M Leistung:
+139.86%
1J Leistung:
+60.50%
1-Tages-Spanne:
$1.775
$1.96
1-Wochen-Bereich:
$1.72
$2.4275
52-Wochen-Spanne:
$0.40
$3.095
Cytomx Therapeutics Inc Stock (CTMX) Company Profile
Firmenname
Cytomx Therapeutics Inc
Sektor
Branche
Telefon
650.515.3185
Adresse
151 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
Vergleichen Sie CTMX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CTMX
Cytomx Therapeutics Inc
|
1.91 | 290.25M | 101.21M | -569.00K | -56.88M | -0.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
392.79 | 100.07B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.41 | 59.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
448.91 | 58.03B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
653.83 | 39.93B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
321.36 | 36.82B | 3.81B | -644.79M | -669.77M | -6.24 |
Cytomx Therapeutics Inc Stock (CTMX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-31 | Eingeleitet | Oppenheimer | Outperform |
| 2025-05-15 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2025-04-14 | Fortgesetzt | Piper Sandler | Overweight |
| 2024-05-28 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2024-05-09 | Hochstufung | Wedbush | Neutral → Outperform |
| 2024-05-06 | Hochstufung | Jefferies | Hold → Buy |
| 2024-04-22 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2022-11-14 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2022-07-07 | Herabstufung | Jefferies | Buy → Hold |
| 2022-07-07 | Herabstufung | Mizuho | Buy → Neutral |
| 2022-07-07 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-07-07 | Herabstufung | Wedbush | Outperform → Neutral |
| 2022-06-24 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-01-18 | Hochstufung | Barclays | Underweight → Overweight |
| 2021-11-15 | Eingeleitet | BTIG Research | Buy |
| 2021-05-28 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2021-03-29 | Eingeleitet | JP Morgan | Overweight |
| 2021-03-23 | Hochstufung | Jefferies | Hold → Buy |
| 2020-09-22 | Herabstufung | Guggenheim | Buy → Neutral |
| 2020-06-01 | Herabstufung | Jefferies | Buy → Hold |
| 2020-05-14 | Bestätigt | H.C. Wainwright | Buy |
| 2020-03-24 | Hochstufung | Wedbush | Neutral → Outperform |
| 2020-03-04 | Eingeleitet | Barclays | Equal Weight |
| 2019-11-20 | Eingeleitet | Guggenheim | Buy |
| 2019-11-11 | Herabstufung | Wedbush | Outperform → Neutral |
| 2019-06-13 | Eingeleitet | Mizuho | Buy |
| 2019-05-14 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2019-03-11 | Eingeleitet | Barclays | Overweight |
| 2018-11-26 | Eingeleitet | Piper Jaffray | Overweight |
| 2018-10-15 | Eingeleitet | Goldman | Neutral |
| 2018-09-13 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-06-01 | Eingeleitet | SunTrust | Buy |
| 2018-01-05 | Eingeleitet | Citigroup | Buy |
| 2017-09-08 | Eingeleitet | Wedbush | Outperform |
| 2017-03-27 | Eingeleitet | H.C. Wainwright | Buy |
| 2017-03-02 | Eingeleitet | Instinet | Buy |
| 2017-01-03 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2015-11-02 | Eingeleitet | Oppenheimer | Outperform |
Alle ansehen
Cytomx Therapeutics Inc Aktie (CTMX) Neueste Nachrichten
Intraday Charts Show Spike in CytomX Therapeutics Inc. ActivityGap Down & Advanced Swing Trade Entry Plans - sundaytimes.kr
CytomX Therapeutics Inc. stock trend forecastSwing Trade & High Conviction Investment Ideas - Newser
Is this a good reentry point in CytomX Therapeutics Inc.Portfolio Performance Summary & Weekly Watchlist of Top Performers - Newser
News impact scoring models applied to CytomX Therapeutics Inc.2025 Volatility Report & Precise Swing Trade Entry Alerts - Newser
What institutional flow reveals about CytomX Therapeutics Inc.July 2025 Drop Watch & Daily Market Momentum Tracking - Newser
Analyzing CytomX Therapeutics Inc. with multi timeframe chartsPortfolio Risk Report & Safe Swing Trade Setup Alerts - Newser
Identifying reversal signals in CytomX Therapeutics Inc.Weekly Profit Analysis & Weekly Market Pulse Alerts - Newser
Technical analysis overview for CytomX Therapeutics Inc. stockJuly 2025 Pullbacks & Long-Term Growth Plans - Newser
What makes CytomX Therapeutics Inc. stock price move sharplyShare Buyback & High Return Trade Guides - sundaytimes.kr
CytomX's High-Risk, High-Reward ADC Strategy: Can CX-2051 Overcome Safety Hurdles and Deliver Value? - AInvest
Published on: 2025-08-15 21:04:24 - sundaytimes.kr
CytomX to continue Phase I ADC trial despite patient death - Yahoo Finance
CytomX Therapeutics Soars 10.23% on Clinical Trial Progress - AInvest
Is CytomX Therapeutics Inc. stock poised for growth2025 Technical Overview & Community Consensus Picks - Newser
FMR LLC's Strategic Acquisition of CytomX Therapeutics Inc Shares Boosts Biotech Portfolio - AInvest
RSI Suggests Rebound May Be Near in CytomX Therapeutics Inc.July 2025 Intraday Action & AI Driven Stock Reports - metal.it
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Q2 2025 Earnings Call Transcript - MSN
CytomX Therapeutics Earnings Call: Clinical Progress and Financial Strength - MSN
Barclays sees ‘significant potential’ in CytomX’s CX-2051 despite safety event - MSN
Cancer patient dies in clinical trial, drugmaker's stock falls, but the study goes on - The Business Journals
Not Many Are Piling Into CytomX Therapeutics, Inc. (NASDAQ:CTMX) Stock Yet As It Plummets 26% - simplywall.st
Slammed 26% CytomX Therapeutics, Inc. (NASDAQ:CTMX) Screens Well Here But There Might Be A Catch - 富途牛牛
Is CytomX Therapeutics Inc. reversing from oversold territory2025 Key Highlights & Community Verified Swing Trade Signals - Newser
What is HC Wainwright’s Estimate for CTMX FY2026 Earnings? - Defense World
CytomX stock falls after reporting patient death in Phase 1 trial - Investing.com
Declining Stock and Solid Fundamentals: Is The Market Wrong About CytomX Therapeutics, Inc. (NASDAQ:CTMX)? - 富途牛牛
CytomX Therapeutics Updates on CX-2051 Phase 1 Study - TipRanks
CytomX Therapeutics Provides Update on CX-2051 Phase 1 Study | C - GuruFocus
CytomX Therapeutics reports safety update in CX-2051 Phase 1 study - Investing.com Nigeria
CytomX Therapeutics provides update on CX-2051 Phase 1 study - MarketScreener
CytomX Therapeutics Provides Update On CX-2051 Phase 1 Study - TradingView
CytomX Cancer Drug Trial Continues Despite Patient Death, Phase 1 Data Expected Q1 2026 - Stock Titan
HC Wainwright Issues Pessimistic Outlook for CTMX Earnings - Defense World
Published on: 2025-08-13 07:49:54 - sundaytimes.kr
CytomX Therapeutics Reports Strong Financial Turnaround - TipRanks
CytomX Therapeutics (CTMX.O) Surges 11.9% — What’s Behind the Unusual Move? - AInvest
CytomX Therapeutics Inc. Inches Above Key Support — Safe to HoldMarket Momentum Signal Generator Shows Trends - beatles.ru
CytomX Therapeutics Reports Improved Financials, Net Income Reaches $23.4 Million - AInvest
CytomX Therapeutics (CTMX): Navigating a Financial Downturn While Advancing Groundbreaking Cancer Therapies - AInvest
CytomX Therapeutics: Updated Outlook For Late 2025 (NASDAQ:CTMX) - Seeking Alpha
CytomX Therapeutics shares fall 2.51% after-hours following Q2 2025 earnings call. - AInvest
Transcript : CytomX Therapeutics, Inc., Q2 2025 Earnings Call, Aug 07, 2025 - MarketScreener
CytomX Therapeutics (CTMX) Reports Break-Even Earnings for Q2 - NewsBreak: Local News & Alerts
Earnings call transcript: CytomX Q2 2025 results show revenue decline, stock dips - Investing.com
CytomX Therapeutics Inc (CTMX) Q2 2025 Earnings Call Highlights: Strategic Advances Amid ... - Yahoo Finance
CytomX Therapeutics Inc (CTMX) Q2 2025 Earnings Call Highlights: Strategic Advances Amid ... By GuruFocus - Investing.com Canada
CytomX Therapeutics Inc (CTMX) Q2 2025 Earnings Call Highlights: Strategic Advances Amid Revenue Decline - GuruFocus
CytomX Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
CytomX Therapeutics Posts Q2 2025 Financials, Announces Positive CX-2051 Results, and Extends Runway to Q2 2027. - AInvest
CytomX Therapeutics Files $250M Mixed Securities Shelf for Future Fundraising - AInvest
CytomX Reports Q2 Revenue Drop of 26%, Narrows Operating Losses Amid Pipeline Progress - AInvest
Finanzdaten der Cytomx Therapeutics Inc-Aktie (CTMX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Cytomx Therapeutics Inc-Aktie (CTMX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Ogden Christopher | Chief Financial Officer |
Jun 16 '25 |
Sale |
2.69 |
10,614 |
28,540 |
226,271 |
| Ogden Christopher | Chief Financial Officer |
Jun 13 '25 |
Sale |
2.95 |
1,641 |
4,841 |
199,385 |
| BELVIN MARCIA | SVP, Chief Scientific Officer |
Jun 13 '25 |
Option Exercise |
0.00 |
37,500 |
0 |
286,136 |
| BELVIN MARCIA | SVP, Chief Scientific Officer |
Jun 16 '25 |
Sale |
2.69 |
13,884 |
37,334 |
272,252 |
| McCarthy Sean A. | CEO |
Jun 13 '25 |
Option Exercise |
0.00 |
150,000 |
0 |
1,145,195 |
| McCarthy Sean A. | CEO |
Jun 16 '25 |
Sale |
2.69 |
55,511 |
149,264 |
1,089,684 |
| McCarthy Sean A. | CEO |
Mar 18 '25 |
Sale |
0.60 |
37,656 |
22,556 |
995,195 |
| Ogden Christopher | Chief Financial Officer |
Mar 18 '25 |
Sale |
0.60 |
8,551 |
5,122 |
201,026 |
| Chu Yu-Waye | Chief Medical Officer |
Mar 18 '25 |
Sale |
0.60 |
4,025 |
2,411 |
135,725 |
| ROWLAND LLOYD A | General Counsel |
Mar 18 '25 |
Sale |
0.60 |
10,203 |
6,112 |
120,594 |
0.41%
0.88%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):